403
Sorry!!
Error! We're sorry, but the page you were
looking for doesn't exist.
Saudi- Medtronic introduces absorbable Antibacterial Envelope in Kingdom
(MENAFN- Arab News) Medtronic Inc. has launched the TYRX absorbable Antibacterial Envelope in Saudi Arabia. This innovative mesh envelope covers an implantable cardiac device to help stabilize the device after implantation and reduce surgical-site infections. The first implants were performed last month by Dr. Azam Shafquat and Dr. Bandar Al-Ghamdi at King Faisal Specialist Hospital and Research Center in Riyadh.
The efficacy of the previous generation non-absorbable TYRX Antibacterial Envelope has been shown in three published studies with new six-month follow-up data from the CITADEL/CENTURION Study presented at Cardiostim 2014.
Six months following implantation patients who received a single- or dual-chamber implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT) replacement device with a TYRX Antibacterial Envelope experienced lower infection rates than a historical cohort of patients who were implanted without the envelope.
Specifically infection occurred in 0.2 percent of patients who received the envelope during an ICD or CRT implant compared to 1.9 percent of patients who did not receive the envelope.
Additionally the rate of device mechanical complications was low (4.0 percent) in patients who received the envelope.
CITADEL/CENTURION is a multicentre study involving 55 sites in the United States that prospectively treated more than 1000 patients undergoing an ICD or CRT replacement with the TYRX Antibacterial Envelope; the primary endpoints were major infection (involving any site other than skin or subcutaneous tissue of the incision or endocarditis) and device mechanical complication.
'Feedback for the bacterial envelope from my perspective is quite positive. It was easy to use and is thin enough so that I did not have to make the pocket bigger. I like it and I think we will be using more than what I had originally anticipated' said Dr. Azam Shafquat consultant electrophysiologist at King Faisal Specialist Hospital and Research Center in Riyadh.
The efficacy of the previous generation non-absorbable TYRX Antibacterial Envelope has been shown in three published studies with new six-month follow-up data from the CITADEL/CENTURION Study presented at Cardiostim 2014.
Six months following implantation patients who received a single- or dual-chamber implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT) replacement device with a TYRX Antibacterial Envelope experienced lower infection rates than a historical cohort of patients who were implanted without the envelope.
Specifically infection occurred in 0.2 percent of patients who received the envelope during an ICD or CRT implant compared to 1.9 percent of patients who did not receive the envelope.
Additionally the rate of device mechanical complications was low (4.0 percent) in patients who received the envelope.
CITADEL/CENTURION is a multicentre study involving 55 sites in the United States that prospectively treated more than 1000 patients undergoing an ICD or CRT replacement with the TYRX Antibacterial Envelope; the primary endpoints were major infection (involving any site other than skin or subcutaneous tissue of the incision or endocarditis) and device mechanical complication.
'Feedback for the bacterial envelope from my perspective is quite positive. It was easy to use and is thin enough so that I did not have to make the pocket bigger. I like it and I think we will be using more than what I had originally anticipated' said Dr. Azam Shafquat consultant electrophysiologist at King Faisal Specialist Hospital and Research Center in Riyadh.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
No comment